Trial Profile

A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nemolizumab (Primary)
Indications Prurigo nodularis
Focus Adverse reactions
Acronyms OLYMPIA LTE
Sponsors Galderma

Most Recent Events

27 Feb 2026 According to a Galderma media release, results from this study to be presented at 2026 Winter Clinical™ Miami, mark the longest LTE study in prurigo nodularis reported to date
27 Feb 2026 Results presented in the Galderma Media Release.
18 Jun 2025 According to a Galderma media release, interim analysis of the OLYMPIA long-term extension study will be presented as a late-breaking session at ICD, on Saturday, June 21, 2025 at 08:30 AM CET.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com